Overview:

Summary

GlobalData, the industry analysis specialist, has released its new report, “Genital Herpes Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Genital Herpes Therapeutics market. The report identifies the key trends shaping and driving the global Genital Herpes Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Genital Herpes Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Genital Herpes Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Genital Herpes Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Genital Herpes Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Genital Herpes Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Genital Herpes Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Genital Herpes Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Genital Herpes Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Genital Herpes Therapeutics market landscape? – Identify, understand and capitalize."

Companies Mentioned

Astellas
AiCuris GmbH & Co. KG
Starpharma Holdings Limited
GlaxoSmithKline plc
Novartis AG

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Genital Herpes - Introduction 6
2.1 Overview 6
2.2 Epidemiology 6
2.3 Etiology 6
2.4 Clinical Presentation/Symptoms 6
2.5 Prognosis 7
2.6 Diagnosis 7
2.6.1 Clinical Examination 7
2.6.2 Viral Culture 7
2.6.3 Polymerase Chain Reaction (PCR) 7
2.6.4 Blood Test 8
2.7 Pathophysiology 8
2.8 Treatment 8
2.9 Prevention 8
2.10 GlobalData Pipeline Report Guidance 9
3 Genital Herpes Therapeutics Market: Market Characterization 10
3.1 Global Markets - Market Size (2005-2010) 10
3.2 Global Markets, Market Forecast (2010-2017) 12
3.3 The US Market Size (2005-2010) 13
3.4 The US Market Forecast (2010-2017) 14
3.5 The UK Market Size (2005-2010) 15
3.6 The UK Market Forecast (2010-2017) 16
3.7 Germany Market Size (2005-2010) 17
3.8 Germany Market Forecast (2010-2017) 18
3.9 France Market Size (2005-2010) 19
3.10 France Market Forecast (2010-2017) 20
3.11 Spain Market Size (2005-2010) 21
3.12 Spain Market Forecast (2010-2017) 22
3.13 Italy Market Size (2005-2010) 23
3.14 Italy Market Forecast (2010-2017) 24
3.15 Japan Market Size (2005-2010) 25
3.16 Japan Market Forecast (2010-2017) 26
3.17 Drivers and Barriers for the Genital Herpes Market 27
3.17.1 Genital Herpes Market Drivers 27
3.17.2 Genital Herpes Infections Market Barriers 27
3.18 Opportunity and Unmet Need 28
3.19 Key Takeaway 29
4 Genital Herpes Therapeutics - Competitive Assessment 30
4.1 Overview 30
4.2 Strategic Competitor Assessment 30
4.3 Product Profile for the Major Marketed Products in the Genital Herpes Market 31
4.3.1 Acyclovir (Zovirax) 31
4.3.2 Valacyclovir (Valtrex) 32
4.3.3 Famciclovir (Famvir) 33
4.4 Key Take Away 34
5 Genital Herpes Therapeutics - Pipeline Assessment 35
5.1 Overview 35
5.2 Strategic Pipeline Assessment 35
5.3 Genital Herpes Market – Pipeline Analysis by Phase of Development 35
5.3.1 Genital Herpes Market – Phase II Clinical Pipeline 35
5.3.2 Genital Herpes Market – Phase I Clinical Pipeline 35
5.3.3 Genital Herpes Market – Pre-clinical Pipeline 36
5.4 Genital Herpes Market – Pipeline by Mechanism of Action 36
5.5 Technology Trends Analytical Framework 37
5.6 Genital Herpes Market – Most Promising Drugs Under Clinical Development 38
5.7 Most Promising Drug Profiles 38
5.7.1 VivaGel (SPL7013 Gel) 38
5.7.2 AIC316 39
5.7.3 ASP2151 40
5.8 Key Takeaway 40
6 Genital Herpes Therapeutics - Implications for Future Market Competition 41
7 Genital Herpes Therapeutics - Clinical Trials Mapping 42
7.1 Clinical Trials by Region/Country (US, EU5, and Japan) 42
7.2 Clinical Trials by Phase of Clinical Development 43
7.3 Clinical Trials by Trial Status 44
7.4 Overall Sponsors 45
7.5 Prominent Sponsors 45
7.6 Brief Profiles of Top 10 Companies Participating in Therapeutics Clinical Trials 46
8 Genital Herpes Therapeutics - Strategic Assessment 47
8.1 Key Events Impacting the Future Market 47
9 Genital Herpes Therapeutics - Future Players 48
9.1 Introduction 48
9.2 Company Profiles 49
9.2.1 Astellas 49
9.2.2 AiCuris GmbH & Co. KG 53
9.2.3 Starpharma Holdings Limited 53
9.2.4 GlaxoSmithKline plc 55
9.2.5 Novartis AG 60
10 Genital Herpes Therapeutics - Licensing and Partnership Deals 70
11 Genital Herpes Therapeutics - Appendix 71
11.1 Definitions 71
11.2 Acronyms 71
11.3 Research Methodology 72
11.3.1 Coverage 72
11.3.2 Secondary Research 72
11.3.3 Forecasting 73
11.3.4 Primary Research 75
11.3.5 Expert Panel Validation 75
11.4 Contact Us 75
11.5 Disclaimer 75
11.6 Bibliography 76"

1.1 List of Tables
Table 1: Diagnostic Procedures Comparison in the Genital Herpes Therapeutics Market, 2010 8
Table 2: Genital Herpes Therapeutics, Global Markets, Revenue ($bn), 2005–2010 11
Table 3: Genital Herpes Therapeutics, Global Markets, Market Forecasts ($bn), 2010–2017 12
Table 4: Genital Herpes Therapeutics Market, the US, Revenue ($bn), 2005–2010 13
Table 5: Genital Herpes Therapeutics Market, the US, Market Forecasts ($bn), 2010–2017 14
Table 6: Genital Herpes Therapeutics, the UK, Revenue ($m), 2005–2010 15
Table 7: Genital Herpes Therapeutics Market, the UK, Market Forecasts ($m), 2010–2017 16
Table 8: Genital Herpes Therapeutics, Germany, Revenue ($m), 2005–2010 17
Table 9: Genital Herpes Therapeutics Market, Germany, Market Forecasts ($m), 2010–2017 18
Table 10: Genital Herpes Therapeutics, France, Revenue ($m), 2005–2010 19
Table 11: Genital Herpes Therapeutics Market, France, Market Forecasts ($m), 2010–2017 20
Table 12: Genital Herpes Therapeutics, Spain, Revenue ($m), 2005–2010 21
Table 13: Genital Herpes Therapeutics Market, Spain, Market Forecasts ($m), 2010–2017 22
Table 14: Genital Herpes Therapeutics, Italy, Revenue ($m), 2005–2010 23
Table 15: Genital Herpes Therapeutics, Italy, Revenue ($m), 2010–2017 24
Table 16: Genital Herpes Therapeutics Market, Japan, Revenue ($m), 2005–2010 25
Table 17: Genital Herpes Therapeutics Market, Japan, Market Forecasts ($m), 2010–2017 26
Table 18: Global, Acyclovir Revenue ($m), 2005-2010 32
Table 19: Global, Valacyclovir Revenue ($m), 2005-2010 33
Table 20: Genital Herpes Market – Phase II Clinical Pipeline, 2010 35
Table 21: Genital Herpes Market – Phase I Clinical Pipeline, 2010 35
Table 22: Genital Herpes Market – Pre-clinical Pipeline, 2010 36
Table 23: Genital Herpes Therapeutics Market – Most Promising Drugs Under Clinical Development, 2010 38
Table 24: Genital Herpes Therapeutics Market, Global, Clinical Trials, 2010 42
Table 25: Genital Herpes Therapeutics Market, Global, Clinical Trials by Phase, 2010 43
Table 26: Genital Herpes Therapeutics Market, Global, Clinical Trials by Status of Development, 2010 44
Table 27: Genital Herpes Therapeutics Market, Global, Prominent Sponsors, 2010 45
Table 28: Genital Herpes Therapeutics and Prophylactic Market, Global, Companies by Phase, 2010 46
Table 29: Astellas Deals, Alliances and Partnerships 49
Table 30: Astellas, Genital Herpes Therapeutic Pipeline, 2010 52
Table 31: Aicuris Deals, Alliances and Partnerships 53
Table 32: Aicuris, Genital Herpes Therapeutic Pipeline, 2010 53
Table 33: Starpharma Deals, Alliances and Partnerships 54
Table 34: Starpharma, Genital Herpes Therapeutic Pipeline, 2010 55
Table 35: GlaxoSmithKline Deals, Alliances and Partnerships 56
Table 36: Novartis Deals 61
Table 37: Genital Herpes Therapeutics, Deals 70"

1.2 List of Figures
Figure 1: Genital Herpes Therapeutics, Global Markets, Revenue ($bn), 2005–2010 10
Figure 2: Genital Herpes Therapeutics, Global Markets, Market Forecasts ($bn), 2010–2017 12
Figure 3: Genital Herpes Therapeutics Market, the US, Revenue ($bn), 2005–2010 13
Figure 4: Genital Herpes Therapeutics Market, the US, Market Forecasts ($bn), 2010–2017 14
Figure 5: Genital Herpes Therapeutics Market, the UK, Revenue ($m), 2005–2010 15
Figure 6: Genital Herpes Therapeutics Market, the UK, Market Forecast ($m), 2010–2017 16
Figure 7: Genital Herpes Therapeutics Market, Germany, Revenue ($m), 2005–2010 17
Figure 8: Genital Herpes Therapeutics Market, Germany, Market Forecast ($m), 2010–2017 18
Figure 9: Genital Herpes Therapeutics Market, France, Revenue ($m), 2005–2010 19
Figure 10: Genital Herpes Therapeutics Market, France, Market Forecast ($m), 2010–2017 20
Figure 11: Genital Herpes Therapeutics Market, Spain, Revenue ($m), 2005–2010 21
Figure 12: Genital Herpes Therapeutics Market, Spain, Market Forecast ($m), 2010–2017 22
Figure 13: Genital Herpes Therapeutics Market, Italy, Revenue ($m), 2005–2010 23
Figure 14: Genital Herpes Therapeutics Market, Italy, Market Forecast ($m), 2010–2017 24
Figure 15: Genital Herpes Therapeutics Market, Japan, Revenue ($m), 2005–2010 25
Figure 16: Genital Herpes Therapeutics Market, Japan, Market Forecast ($m), 2010–2017 26
Figure 17: Opportunity and Unmet Need in the Genital Herpes Therapeutics Market 28
Figure 18: Strategic Competitor Assessment, 2010 30
Figure 19: Genital Herpes Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2010 36
Figure 20: Genital Herpes Therapeutics Market – Clinical Pipeline by Phase of Development, 2010 36
Figure 21: Technology Trends Analytics Framework, 2010 37
Figure 22: Technology Trends Analytics Framework – Description, 2010 37
Figure 23: Genital Herpes Therapeutics Implication For Future Market Competition 41
Figure 24: Genital Herpes Therapeutics Market, Global, Clinical Trials by Country, 2010 42
Figure 25: Genital Herpes Therapeutics Market, Global, Clinical Trials by Phase, 2010 43
Figure 26: Genital Herpes Therapeutics Market, Global, Clinical Trials by Status of Development, 2010 44
Figure 27: Genital Herpes Therapeutics Market, Global, Prominent Sponsors, 2010 45
Figure 28: Genital Herpes Therapeutics Market, Global, Prominent Sponsors, 2010 45
Figure 29: Genital Herpes Therapeutics Market, Global, Companies by Phase, 2010 46
Figure 30: Genital Herpes Therapeutics Market, Drivers and Restraints 2010 47
Figure 31: Genital Herpes Therapeutics Market – Clinical Pipeline by Company, 2010 48
Figure 32: GlobalData Market Forecasting Model 74